KUALA LUMPUR 7 April 2026 (The Capital Post) – Ekuiti Nasional Bhd (Ekuinas) has announced a strategic investment in Ain Medicare Sdn Bhd, a prominent home-grown Bumiputera manufacturer of sterile parenteral pharmaceutical products, in a move to bolster local capacity in the healthcare sector.
The investment was made through Ekuinas’ RM1 billion Tranche IV fund, under which the firm will acquire a minority shareholding in Ain Medicare, aligning with its mandate to scale up Bumiputera enterprises in sectors deemed critical for Malaysia’s long-term economic resilience.
Ekuinas Chief Executive Officer Aliff Omar Mohamad Omar highlighted the robust growth prospects of Malaysia’s pharmaceutical industry, projected to expand significantly in response to rising healthcare demand, demographic changes and strengthening domestic manufacturing capabilities.
He added that institutional capital plays a vital role in supporting scalable local players in priority industries, noting that the pharmaceutical sector’s fundamentals are underpinned by regulatory enhancements, export opportunities and innovation in specialised products.
-Advertisement-
Ain Medicare, which operates multiple manufacturing facilities in Kota Bharu and Kulim and holds local and international certifications for quality and regulatory compliance, is expected to benefit from Ekuinas’ capital and strategic guidance as it expands its footprint.
The partnership reflects a broader commitment to strengthening Bumiputera participation in key economic segments while contributing meaningfully to Malaysia’s industrial development agenda. -The Capital Post